Mercato chiuso -
Altri mercati azionari
|
Variaz. 5gg | Var. 1 gen. | ||
228,4 BRL | -10,24% | +4,08% | -8,58% |
Attività
Gli Stati Uniti rappresentano il 70,1% delle vendite nette.
Numero di dipendenti: 34 100
Vendite per attività
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Innovative Medicines
100,0
%
| 46 159 | 100,0 % | 45 006 | 100,0 % | -2,50% |
Vendite per regione
USD in Milioni | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
70,1
%
| 31 828 | 69,0 % | 31 555 | 70,1 % | -0,86% |
International
28,3
%
| 13 497 | 29,2 % | 12 752 | 28,3 % | -5,52% |
Other
1,6
%
| 834 | 1,8 % | 699 | 1,6 % | -16,19% |
Dirigenti
Dirigenti | Titolo | Età | Da |
---|---|---|---|
Chief Executive Officer | 53 | 01/02/15 | |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Greg Meyers
CTO | Chief Tech/Sci/R&D Officer | - | - |
Compliance Officer | - | 01/01/03 | |
Chief Tech/Sci/R&D Officer | - | - | |
Samit Hirawat
CTO | Chief Tech/Sci/R&D Officer | 55 | 01/01/19 |
Robert Plenge
CTO | Chief Tech/Sci/R&D Officer | 53 | 01/11/19 |
Laura Hortas
IRO | Public Communications Contact | - | - |
Corporate Officer/Principal | - | - | |
Cari Gallman
PRN | Corporate Officer/Principal | - | - |
Amministratori
Amministratori | Titolo | Età | Da |
---|---|---|---|
Phyllis Yale
BRD | Director/Board Member | 66 | 20/11/19 |
Peter Arduini
BRD | Director/Board Member | 59 | 01/04/16 |
Derica Rice
BRD | Director/Board Member | 59 | 01/09/20 |
Paula Price
BRD | Director/Board Member | 62 | 01/09/20 |
Theodore Samuels
BRD | Director/Board Member | 69 | 21/02/17 |
David Elkins
DFI | Director of Finance/CFO | 55 | 20/11/19 |
Chief Executive Officer | 53 | 01/02/15 | |
Julia Haller
BRD | Director/Board Member | 69 | 20/11/19 |
Deepak Bhatt
BRD | Director/Board Member | 56 | 14/06/22 |
Karen Vousden
BRD | Director/Board Member | 66 | 01/01/18 |
Classe di azioni
Voto | Quantità | Flottante | Autocontrollo | Flottante totale | |
---|---|---|---|---|---|
Azione A | 1 | 2 923 100 096 | 2 024 918 592 ( 69,27 %) | 896 000 000 ( 30,65 %) | 69,27 % |
Partecipazioni
Nome | Azioni | % | Valorizzazione |
---|---|---|---|
5 075 304 | 5.31% | 136 322 665 $ | |
759 145 | 6.36% | 19 358 198 $ | |
COMPUGEN LTD. 5.31% | 4 757 058 | 5.31% | 10 322 816 $ |
CELULARITY INC. 5.49% | 1 195 327 | 5.49% | 3 717 467 $ |
Coordinate società
Bristol Myers Squibb Co.
Route 206 & Province Line Road
08543, Princeton
+609 252 4621
http://www.bms.comSocietà del gruppo
Nome | Categoria e settore |
---|---|
Bristol-Myers Squibb India Pvt Ltd.
Bristol-Myers Squibb India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb India Pvt Ltd. discovers, develops and delivers medicines for immuno-oncology. The company is based in Mumbai, India. |
Pharmaceuticals: Major
|
Bristol-Myers Squibb de México S de RL de CV
Bristol-Myers Squibb de México S de RL de CV Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Bristol-Myers Squibb de México S de RL de CV is a Mexican company that manufactures and supplies pharmaceutical and nutritional products. The company is located in Mexico. |
Pharmaceuticals: Major
|
Celgene Kappa Holdings LLC
| |
Bristol-Myers Squibb International Co. ULC
| |
Bristol-Myers Squibb Holdings Germany Verwaltungs GmbH
| |
Seamair Insurance DAC
| |
Bristol-Myers Squibb AE
| |
Swords Laboratories Unlimited Co.
Swords Laboratories Unlimited Co. Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Swords Laboratories Unlimited Co. is a pharmaceutical company that manufactures pharmaceutical products. The company is based in Swords, Ireland. |
Pharmaceuticals: Major
|
BMS Strategic Portfolio Investments Holdings, Inc.
|
Settore
Vendite per regione
Revisioni EPS
Variaz. 1 gen. | Capi. | |
---|---|---|
+48,39% | 765 Mrd | |
-6,13% | 354 Mrd | |
+20,61% | 331 Mrd | |
+10,00% | 299 Mrd | |
+18,87% | 248 Mrd | |
-1,96% | 219 Mrd | |
+11,11% | 216 Mrd | |
+5,80% | 164 Mrd | |
-2,50% | 162 Mrd |
- Borsa valori
- Azioni
- Azione BMY
- Azione BMYB34
- Società Bristol-Myers Squibb Company